AYTU BIOPHARMA, INC (AYTU)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 06-30. Amounts in USD.

Revenue Quarterly

0 15M 30M 45M Q4 '21: 23.5M Q1 '22: 21.9M Q2 '22: 23.1M Q3 '22: 24.2M Q4 '22: 27.4M Q1 '23: 27.7M Q2 '23: 26.3M Q3 '23: 22.7M Q4 '23: 30.7M Q1 '24: 17.8M Q2 '24: 18.7M Q3 '24: 14M Q4 '24: 14.6M Q1 '25: 16.6M Q2 '25: 16.2M Q3 '25: 18.5M Q4 '25: 15.1M Q1 '26: 13.9M Q2 '26: 15.2M Q3 '26: 12.4M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Gross Profit Quarterly

0 7M 14M 21M Q4 '21: 11.3M Q1 '22: 12.5M Q2 '22: 12.3M Q3 '22: 12.7M Q4 '22: 14.8M Q1 '23: 18M Q2 '23: 17.3M Q3 '23: 12.7M Q4 '23: 18.6M Q1 '24: 13M Q2 '24: 14.6M Q3 '24: 10.4M Q4 '24: 11.1M Q1 '25: 12M Q2 '25: 10.8M Q3 '25: 12.8M Q4 '25: 10.3M Q1 '26: 9.2M Q2 '26: 9.6M Q3 '26: 7.6M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Operating Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q4 '21: -24.1M Q1 '22: -27.7M Q2 '22: -11.3M Q3 '22: -53.4M Q4 '22: -16.9M Q1 '23: -1.8M Q2 '23: -6.9M Q3 '23: -8.6M Q4 '23: 169K Q1 '24: -867K Q2 '24: 3.1M Q3 '24: -1.6M Q4 '24: -2.3M Q1 '25: -930K Q2 '25: -1.7M Q3 '25: 2.4M Q4 '25: -7.6M Q1 '26: -1.5M Q2 '26: -2M Q3 '26: -4.1M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Net Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q4 '21: -19M Q1 '22: -27.9M Q2 '22: -11.5M Q3 '22: -53.3M Q4 '22: -16.1M Q1 '23: -701K Q2 '23: -6.7M Q3 '23: -7.2M Q4 '23: -2.5M Q1 '24: -8.1M Q2 '24: -220K Q3 '24: -2.9M Q4 '24: -4.6M Q1 '25: 1.5M Q2 '25: 788K Q3 '25: 4M Q4 '25: -19.8M Q1 '26: 2M Q2 '26: -10.6M Q3 '26: -5.6M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Cost of Revenue Quarterly

0 5M 10M 15M Q4 '21: 12.2M Q1 '22: 9.4M Q2 '22: 10.8M Q3 '22: 11.5M Q4 '22: 12.6M Q1 '23: 9.6M Q2 '23: 9M Q3 '23: 10M Q4 '23: 12.2M Q1 '24: 4.8M Q2 '24: 4.1M Q3 '24: 3.7M Q4 '24: 3.5M Q1 '25: 4.6M Q2 '25: 5.4M Q3 '25: 5.6M Q4 '25: 4.9M Q1 '26: 4.7M Q2 '26: 5.5M Q3 '26: 4.8M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Operating Cash Flow Quarterly

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q4 '21: -6.3M Q1 '22: -3.8M Q2 '22: -8.8M Q3 '22: -9.1M Q4 '22: -7.1M Q1 '23: -9.1M Q2 '23: -2.4M Q3 '23: -2.9M Q4 '23: 9.4M Q1 '24: -211K Q2 '24: -135K Q3 '24: -254K Q4 '24: -788K Q1 '25: -1.2M Q2 '25: 2.9M Q3 '25: -6.5M Q4 '25: 2.8M Q1 '26: -618K Q2 '26: 3.7M Q3 '26: -4.2M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Free Cash Flow Quarterly

-14M -7M 0 7M 14M 21M Q3 '17: -2.4M Q4 '17: -3.3M Q3 '18: -4.1M Q4 '18: -4.5M Q1 '19: -2.8M Q2 '19: -4.3M Q3 '19: -3.4M Q4 '19: -3.5M Q1 '20: -3M Q2 '20: -10.6M Q3 '20: 19.2M Q4 '20: -7.8M Q3 '24: -254K Q1 '25: -1.3M Q2 '25: 2.9M Q3 '25: -6.5M Q4 '25: 2.8M Q1 '26: -618K Q2 '26: 3.7M Q3 '26: -4.2M Q4 '17 Q1 '19 Q4 '19 Q3 '20 Q1 '25 Q4 '25 Q3 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 7M 14M 21M Q1 '21: 12.2M Q2 '21: 13.3M Q3 '21: 18.1M Q1 '22: 1.3M Q2 '22: 1.3M Q3 '22: 1.5M Q1 '23: 2.5M Q2 '23: 3.1M Q3 '23: 3.7M Q1 '24: 5.5M Q2 '24: 5.5M Q3 '24: 5.5M Q1 '25: 9.1M Q2 '25: 8.5M Q3 '25: 8.2M Q1 '26: 19.5M Q2 '26: 10M Q3 '26: 10.5M Q3 '21 Q3 '22 Q3 '23 Q3 '24 Q3 '25 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-75.00 -50.00 -25.00 0.00 25.00 50.00 75.00 Q4 '21: -3.25 Q1 '22: -24.66 Q2 '22: -32.68 Q3 '22: -67.17 Q4 '22: -72.28 Q1 '23: -50.80 Q2 '23: -44.21 Q3 '23: -10.24 Q4 '23: -4.76 Q1 '24: -5.96 Q2 '24: -3.85 Q3 '24: -2.44 Q4 '24: -2.86 Q1 '25: -1.53 Q2 '25: -1.75 Q3 '25: -1.02 Q4 '25: -3.38 Q1 '26: -3.31 Q2 '26: -4.10 Q3 '26: -4.84 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.